What it sells
TRIOAR (Trior) is an antibody-based platform developer researching next-generation platform technologies, such as an ADC platform with tumor-microenvironment targeting, to improve the therapeutic index of antibody therapeutics.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-23 | Series C | KRW 33B | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-29.